enGene Therapeutics Inc. Common Stock (ENGN)

FairStock Score: 32/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I approach this as a Graham-style exercise in separating a real business from a story. enGene is a clinical-stage biotechnology company with no reported revenue; its lead candidate, detalimogene voraplasmid, is in Phase 2 for non-muscle invasive bladder cancer. In fiscal Q3 2026, the quarter ended 2026-07-31, it reported a net loss of $32.5 million. For FY2025 ended 2025-10-31, the net loss was $117.3 million, worse than FY2024’s $55.1 million. Free cash flow was negative $104.0 million over the trailing twelve months, and FairStock’s FCF yield calculation is -18.2%. That is not a business generating owner earnings; it is a funded research effort. The balance sheet looks less strained than the income statement: the data show debt-to-equity of 0.14, and FairStock’s Altman Z-score is 4.71, though the Piotroski F-score is 0/9. At the 2026-10-26 close of $1.58, FairStock calculates P/B at 0.46 and P/E at -0.76; a negative earnings multiple tells us little. The market cap is $572.8 million. The stock is far below its 52-week high of $12.25, but low price alone is not value. A durable moat is unproven at this stage; the key asset is clinical hope, not demonstrated earning power. I would demand evidence of trial success, controlled cash burn, and a clear path to profitability before calling this intrinsically cheap. As a speculative biotech, it may be interesting, but it does not meet conservative value tests today.

In plain English: enGene is testing genetic medicines for bladder cancer, with a lead treatment in Phase 2 trials. The company has no reported revenue and is losing money, so the business looks weak today. The stock price is low compared with its accounting value, but because profits are negative, it is hard to call it a simple bargain.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-26 close · note generated 2026-10-28 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q3 2026 10-Q (period ended 2026-07-31) · fiscal Q2 2026 10-Q (period ended 2026-04-30) · fiscal Q1 2026 10-Q (period ended 2026-01-31) · fiscal Q3 2025 10-Q (period ended 2025-07-31) · FY2025 10-K (period ended 2025-10-31) · FY2024 10-K (period ended 2024-10-31) · FY2023 10-K (period ended 2023-10-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer